Prelude Capital Management’s C4 Therapeutics CCCC Stock Holding History

Prelude Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92K	Sell	19,700 -11,257	-36%	-$38.5K	0.01%	1122
2026 Q1	$81.4K	Buy	+30,957	New	+$72.9K	0.01%	1081
2024 Q1	–	Sell	-17,749	Closed	-$100K	–	1331
2023 Q4	$100K	Sell	17,749 -33,400	-65%	-$76.2K	0.01%	1026
2023 Q3	$95.1K	Buy	51,149 +17,149	+50%	+$52.3K	0.01%	1000
2023 Q2	$93.5K	Buy	+34,000	New	+$109K	0.01%	938

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's CCCC Position: Q2 2026 in Review

Prelude Capital Management reduced its C4 Therapeutics (CCCC) stake by 36% in Q2 2026, selling an estimated $38.5K and leaving 19,700 shares worth $92K. The position accounts for 0.01% of the portfolio, ranked #1122.

Prelude Capital Management first reported a position in CCCC in Q2 2023 and has held it in 5 quarters since. The position peaked at $100K in Q4 2023. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Prelude Capital Management held 19,700 shares of C4 Therapeutics worth $92K as of Q2 2026.
Prelude Capital Management sold 11,257 C4 Therapeutics shares in Q2 2026, an estimated $38.5K.
C4 Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1122 holding.
Prelude Capital Management first reported a position in C4 Therapeutics in Q2 2023 and has held it in 5 quarters since.
Prelude Capital Management's C4 Therapeutics position peaked at $100K in Q4 2023.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.